Back to Search
AMELIA GENNARI, MD
MD
Geriatric Medicine (Internal Medicine) Physician
NPI: 1851364848IndividualAccepts Medicare
Specialties, Licenses & Credentials
Specialist
Specialist
Code: 174400000X
MD065297L(PA)
Geriatric Medicine (Internal Medicine) PhysicianPrimary
Internal Medicine — Geriatric Medicine
Code: 207RG0300X
042-0014579(VT)
Education
UNIVERSITY OF VIRGINIA SCHOOL OF MEDICINE
Class of 1992
Research & Publications (20)
Epirubicin plus low-dose trastuzumab in HER2 positive metastatic breast cancer.
PMID 18791821·Breast Cancer Res Treat·2009
3-trial
Relationship between individual ventilatory response and acute renal water excretion at high altitude.
PMID 18539548·Respir Physiol Neurobiol·2008
8-other
HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials.
PMID 18159072·J Natl Cancer Inst·2008
8-other
New understanding of the role of anthracyclines in early-stage breast cancer: patient selection considerations.
PMID 19158039·Clin Breast Cancer·2008
6-review
In vitro tests to evaluate immunotoxicity: a preliminary study.
PMID 17092623·Toxicology·2007
7-preclinical
Mental status impairment in patients with West Haven grade zero hepatic encephalopathy: the role of HCV infection.
PMID 17322997·J Gastroenterol·2007
4-observational
The assessment of repeated dose toxicity in vitro: a proposed approach. The report and recommendations of ECVAM workshop 56.
PMID 16831063·Altern Lab Anim·2006
7-preclinical
Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer.
PMID 16921042·J Clin Oncol·2006
2-rct
Metabolism: a bottleneck in in vitro toxicological test development. The report and recommendations of ECVAM workshop 54.
PMID 16522150·Altern Lab Anim·2006
7-preclinical
Dendritic cells as a tool for the predictive identification of skin sensitisation hazard.
PMID 15807636·Altern Lab Anim·2005
8-other
Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies.
PMID 16149088·Cancer·2005
8-other
Primary chemotherapy with gemcitabine, epirubicin and taxol (GET) in operable breast cancer: a phase II study.
PMID 16052214·Br J Cancer·2005
3-trial
The Use of In Vitro Systems for Evaluating Immunotoxicity: The Report and Recommendations of an ECVAM Workshop.
PMID 18958661·J Immunotoxicol·2005
8-other
Multicentric phase II trial of gemcitabine plus epirubicin plus paclitaxel as first-line chemotherapy in metastatic breast cancer.
PMID 14710202·Br J Cancer·2004
3-trial
Strategies to replace in vivo acute systemic toxicity testing. The report and recommendations of ECVAM Workshop 50.
PMID 15651930·Altern Lab Anim·2004
6-review
HER2 overexpression as a prognostic factor in metastatic breast cancer patients treated with high-dose chemotherapy and autologous stem cell support.
PMID 15273709·Bone Marrow Transplant·2004
8-other
Culturing cells without serum: lessons learnt using molecules of plant origin.
PMID 15195227·ALTEX·2004
7-preclinical
Activity of first-line epirubicin and paclitaxel in metastatic breast cancer is independent of type of adjuvant therapy.
PMID 14997190·Br J Cancer·2004
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
Via practice · 3 locations total
- Address
- 111 COLCHESTER AVE
BURLINGTON, VT 05401 - Phone
- (802) 847-0000
Quick Facts
- NPI
- 1851364848
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 3
- Years in Practice
- 34
- Publications
- 20
Are you this provider?
Claim Your Profile